324 related articles for article (PubMed ID: 37429729)
1. In Vivo Metabolite Profiles of an
Li XQ; Elebring M; Dahlén A; Weidolf L
Drug Metab Dispos; 2023 Oct; 51(10):1350-1361. PubMed ID: 37429729
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
[TBL] [Abstract][Full Text] [Related]
3. Identification of GalNAc-Conjugated Antisense Oligonucleotide Metabolites Using an Untargeted and Generic Approach Based on High Resolution Mass Spectrometry.
Husser C; Brink A; Zell M; Müller MB; Koller E; Schadt S
Anal Chem; 2017 Jun; 89(12):6821-6826. PubMed ID: 28520401
[TBL] [Abstract][Full Text] [Related]
4. Solid-phase synthesis of 5'-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry.
Prakash TP; Brad Wan W; Low A; Yu J; Chappell AE; Gaus H; Kinberger GA; Østergaard ME; Migawa MT; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2015 Oct; 25(19):4127-30. PubMed ID: 26299345
[TBL] [Abstract][Full Text] [Related]
5. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
[TBL] [Abstract][Full Text] [Related]
6. In vitro metabolism of 2'-ribose unmodified and modified phosphorothioate oligonucleotide therapeutics using liquid chromatography mass spectrometry.
Kim J; El Zahar NM; Bartlett MG
Biomed Chromatogr; 2020 Jul; 34(7):e4839. PubMed ID: 32246854
[TBL] [Abstract][Full Text] [Related]
7. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.
Tanowitz M; Hettrick L; Revenko A; Kinberger GA; Prakash TP; Seth PP
Nucleic Acids Res; 2017 Dec; 45(21):12388-12400. PubMed ID: 29069408
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide.
Clewe O; Rekić D; Quartino AL; Carlsson B; Higashimori M; Wernevik L; Hofherr A; Rydén-Bergsten T; Nilsson C; Knöchel J
Br J Clin Pharmacol; 2024 Jun; 90(6):1503-1513. PubMed ID: 38504437
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of 5'-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies.
Cedillo I; Chreng D; Engle E; Chen L; McPherson AK; Rodriguez AA
Molecules; 2017 Aug; 22(8):. PubMed ID: 28809818
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and Disposition of Volanesorsen, a 2'-
Post N; Yu R; Greenlee S; Gaus H; Hurh E; Matson J; Wang Y
Drug Metab Dispos; 2019 Oct; 47(10):1164-1173. PubMed ID: 31350288
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
[TBL] [Abstract][Full Text] [Related]
12. High-sensitivity workflow for LC-MS-based analysis of GalNAc-conjugated oligonucleotides: a case study.
Ledvina AR; Ewles M; Severin P; Good D; Arfvidsson C
Bioanalysis; 2021 Sep; 13(17):1343-1353. PubMed ID: 34470470
[No Abstract] [Full Text] [Related]
13. Effect of modular conjugation strategy for
Yamamoto T; Sawamura M; Terada C; Kashiwada K; Wada F; Yamayoshi A; Obika S; Harada-Shiba M
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):109-118. PubMed ID: 31617782
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor.
Schmidt K; Prakash TP; Donner AJ; Kinberger GA; Gaus HJ; Low A; Østergaard ME; Bell M; Swayze EE; Seth PP
Nucleic Acids Res; 2017 Mar; 45(5):2294-2306. PubMed ID: 28158620
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tissue Distribution, and Metabolism of LNA-Containing Antisense Oligonucleotides in Rats.
Romero-Palomo F; Festag M; Lenz B; Schadt S; Brink A; Kipar A; Steinhuber B; Husser C; Koller E; Sewing S; Tessier Y; Dzygiel P; Fischer G; Winter M; Hetzel U; Mihatsch MJ; Braendli-Baiocco A
Toxicol Pathol; 2021 Aug; 49(6):1174-1192. PubMed ID: 34060347
[TBL] [Abstract][Full Text] [Related]
16. Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides.
Wada F; Yamamoto T; Kobayashi T; Tachibana K; Ito KR; Hamasaki M; Kayaba Y; Terada C; Yamayoshi A; Obika S; Harada-Shiba M
Mol Ther Nucleic Acids; 2021 Dec; 26():957-969. PubMed ID: 34760338
[TBL] [Abstract][Full Text] [Related]
17. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
[TBL] [Abstract][Full Text] [Related]
18. Effect of 2'-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] modification on activity of gapmer antisense oligonucleotides containing 2',4'-constrained 2'-O-ethyl nucleic acid.
Pandey SK; Nowak A; Perkins J; Ferng A; Prakash TP
Bioorg Med Chem Lett; 2015 Apr; 25(8):1688-1691. PubMed ID: 25804718
[TBL] [Abstract][Full Text] [Related]
19. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
